Filing Details

Accession Number:
0001209191-21-012124
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-18 19:06:12
Reporting Period:
2021-02-16
Accepted Time:
2021-02-18 19:06:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
906709 Nektar Therapeutics NKTR Pharmaceutical Preparations (2834) 943134940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808356 Andrew Mark Wilson C/O Nektar Therapeutics
455 Mission Bay Blvd South, Suite 100
San Francisco CA 94158
Svp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-16 2,173 $22.37 76,727 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  2. This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  3. This number includes 3,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).